New data may change the standard of care for patients with advanced non-small cell lung cancer

By | April 25, 2022
The phase 2 clinical trial of a multi-center study known as the COAST clinical trial has demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non-small cell lung cancer, according to researchers at Yale Cancer Center and participating organizations.